Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Validation of TAK228 as an effective drug for treating children ...

Validation of TAK228 as an Effective Drug for Treating Children Diagnosed with DIPG Diffuse intrinsic pontine glioma (DIPG) is an untreatable childhood cancer.  DIPGs develop in pons making them surgically unresectable.  We and others have identified mutations in histone and their obligate partner mutations that seem to drive ...

Developing Novel Combination theraputic approaches for DIPG targeting Polo-like Kinase 1

Whole genome sequencing on DIPG biopsy and autopsy samples have identified specific mutations in Histone H3, ACVRI, TP53 and ATRX causing heterochromatin silencing, genetic instability and alterations in DNA damage response pathways. Using a unique panel of patient derived DIPG cultures, we have further examined the molecular profile of DIPG ...

Toward a multimodality cure for DIPG: investigation of intratumoral drug ...

Diffuse intrinsic pontine glioma (DIPG) is a currently incurable childhood brain tumor that, despite many past clinical trials, has never been shown to respond to systemic chemotherapy. Radiation therapy (RT) is effective in extending life but is not curative; median overall survival is 11 months and long-term survival is extremely rare.1 ...

TARGETING NEURONAL ACTIVITY-REGULATED DIPG INFILTRATION (2017)

DIPG is characteristically infiltrative (i.e. diffuse and intrinsic), and this infiltrative/invasive behavior is destructive both in the brainstem and in other areas of the central nervous system to which DIPG spreads during the course of the disease. In work previously funded by the Cure Starts Now and the ...

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: as in ...

Diffuse intrinsic pontine gliomas (DIPG) are infiltrative, highly aggressive pediatric brainstem tumors with limited therapeutic options. Despite international efforts to improve outcome, DIPG show poor response to conventional radiation and chemotherapeutic strategies. Only within the last decade have studies really begun to decipher the molecular mechanisms behind DIPG tumorigenesis, with ...

Targeting EZH2 as a theraputic strategy in DIPG

Malignant brain tumors are the leading cause of cancer-related mortality in children (1), and diffuse intrinsic pontine glioma (DIPG) is one of the most devastating, with a median survival of <1 year following treatment with radiation therapy (2). Despite more than 250 clinical trials over the past 30 years (3), not a single chemotherapeutic agent ...